Business Wire

BRIGADE-M3

25.5.2023 17:31:28 CEST | Business Wire | Press release

Share
Brigade-M3 European Acquisition Corp. Redemption notice

Brigade-M3 European Acquisition Corp. (the "Company"), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V. ("Euronext Amsterdam"), today announces that it will not conclude a business combination before its business combination deadline on 14 June 2023 (the "Business Combination Deadline"). Therefore, the board of directors of the Company (the "Board") resolved to initiate the redemption of all listed unit shares and ordinary shares in the share capital of Company (the "Units" and "Ordinary Shares", respectively) following the Business Combination Deadline in accordance with the terms and conditions for the redemption of the Units and Ordinary Shares in the Company's articles of association and as disclosed in the Company's IPO prospectus dated 8 December 2021 (the "Prospectus").

Since the Company became listed on Euronext Amsterdam on 14 December 2021, the Company has been searching for a target to consummate a business combination. During this period, the Company has investigated various potential targets and held explorative talks with a selection of them, but despite extensive efforts to date, the Company has not been able to find a suitable target for a business combination. As the Business Combination Deadline is forthcoming, the Board deems it highly unlikely that the Company will be able to complete a business combination before the Business Combination Deadline and, therefore, the Board has decided to initiate the redemption of the Units and Ordinary Shares following the Business Combination Deadline. In accordance with the disclosure in the Prospectus, the Company will procure that the amount held in the Escrow Account will be returned to the holders of Units and Ordinary Shares as promptly as reasonably possible but not more than ten trading days after the Business Combination Deadline.

Holders of Units and Ordinary Shares will receive redemption proceeds from the Escrow Account through payment by the Company's Listing Agent, at an expected price per Unit or Ordinary Share of $10.20 plus accrued interest (this amount comprises of (i) $10.00 initial subscription price; (ii) $0.20 escrow overfunding by the Company's sponsor; and (iii) the pro rata part of the accrued interest on the Escrow Account). Holders of Units and Ordinary Shares will receive this payment in exchange for the delivery of the Units or Ordinary Shares via the shareholder’s intermediary to the Listing Agent. As a result of the Company not completing a business combination before the Business Combination Deadline, the public warrants and the sponsor warrants will automatically expire without value on the Business Combination Deadline in line with the terms and conditions of the warrants and the disclosure in the Prospectus. There will be no distribution of proceeds or otherwise from the Escrow Account with respect to the public warrants or the sponsor warrants.

Indicative timetable

The timetable below sets forth certain expected key dates for the redemption of the Units and Ordinary Shares.

Event

   

Date

Business Combination Deadline

   

14 June 2023

Last trading day

14 June 2023

Expiration of sponsor warrants and public warrants

   

15 June 2023

Record date for the redemption of Units and Ordinary Shares

   

16 June 2023

Payment of redemption proceeds

   

20 June 2023

Redemption of Units and Ordinary Shares

   

21 June 2023

Post-Redemption

Following the Business Combination Deadline and the redemption of the Units and Ordinary Shares (and the expiration of the public warrants and the sponsor warrants), the only outstanding securities of the Company will be the sponsor shares. The Board intends to seek sponsor shareholder approval to adopt amended and restated memorandum and articles of association in order to facilitate the re-purposing and continuation of the Company, subject to additional capital being committed by the sponsor for such purpose. The redeemed Units and Ordinary Shares will be held in treasury by the Company for the purpose of re-allocating such Units and Ordinary Shares in the future.

IMPORTANT INFORMATION

This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

DISCLAIMER

This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does not contain or constitute an offer of securities for sale or an invitation or offer to the public for securities in any jurisdiction.

In the EEA, this announcement is only directed at persons who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (EU 2017/1129) as amended. In the United Kingdom, this announcement is directed only at “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (EU) No 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005640/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release

Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye